作者：
Shouyan,Deng [1]
;
Yibo,Zhang [1]
;
Huanbin,Wang [2]
;
Wenhua,Liang [3]
;
Lu,Xie [4]
;
Ning,Li [5]
;
Yuan,Fang [5]
;
Yiting,Wang [1]
;
Jiayang,Liu [1]
;
Hao,Chi [1]
;
Yufan,Sun [2]
;
Rui,Ye [2]
;
Lishen,Shan [2]
;
Jiawei,Shi [1]
;
Zan,Shen [6]
;
Yonggang,Wang [6]
;
Shuhang,Wang [5]
;
Jean-Philippe,Brosseau [7]
;
Feng,Wang [3]
;
Grace,Liu [8]
;
Yingfei,Quan [2]
;
Jie,Xu [9]
作者单位：
Institutes of Biomedical Sciences, Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology), Zhongshan-Xuhui Hospital, Fudan University, Shanghai 200032, China.
[1]
BioTroy Therapeutics, Shanghai 201400, China.
[2]
Shanghai Institute of Immunology, School of Medicine, Shanghai Jiao Tong University, Shanghai 200031, China.
[3]
Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing 100044, China.
[4]
Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100020, China.
[5]
Department of Oncology, Shanghai Sixth People's Hospital Affiliated with Shanghai Jiao Tong University School of Medicine, No. 600, Yishan Road, Shanghai 200233, China.
[6]
Department of Biochemistry and Functional Genomics, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1E 4K8, Canada.
[7]
Arctic Animal Hospital, Fuzhou, Fujian 350007, China.
[8]
Institutes of Biomedical Sciences, Shanghai Key Laboratory of Medical Epigenetics, International Co-laboratory of Medical Epigenetics and Metabolism (Ministry of Science and Technology), Zhongshan-Xuhui Hospital, Fudan University, Shanghai 200032, China. Electronic address: jie_xu@fudan.edu.cn.
[9]
DOI
10.1016/j.cell.2024.03.019
PMID
38614099
发布时间
2024-04-26
换一批
换一批
